{
  "ticker": "OCGN",
  "company_name": "Ocugen, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05258669",
      "title": "Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults",
      "status": "UNKNOWN",
      "phase": "PHASE2, PHASE3",
      "condition": "COVID-19",
      "start_date": "2022-02-20",
      "completion_date": "2023-10-31",
      "enrollment": 0,
      "sponsor": "Ocugen"
    },
    {
      "nct_id": "NCT05541289",
      "title": "Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN\u2122 (BBV152) in Adults Aged 18 Years and Older",
      "status": "NO_LONGER_AVAILABLE",
      "phase": "",
      "condition": "COVID-19",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Ocugen"
    },
    {
      "nct_id": "NCT06018558",
      "title": "Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Geographic Atrophy",
      "start_date": "2023-02-23",
      "completion_date": "2026-05-29",
      "enrollment": 0,
      "sponsor": "Ocugen"
    },
    {
      "nct_id": "NCT05802329",
      "title": "Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Center Involved Diabetic Macular Edema, Diabetic Macular Edema",
      "start_date": "2024-01-13",
      "completion_date": "2026-07-31",
      "enrollment": 0,
      "sponsor": "Ocugen"
    },
    {
      "nct_id": "NCT03785340",
      "title": "Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Dry Eye",
      "start_date": "2018-12-03",
      "completion_date": "2019-02-25",
      "enrollment": 0,
      "sponsor": "Ocugen"
    },
    {
      "nct_id": "NCT03418727",
      "title": "Dry Eye Disease Study With Brimonidine",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Dry Eye",
      "start_date": "2017-09-06",
      "completion_date": "2018-03-29",
      "enrollment": 0,
      "sponsor": "Ocugen"
    },
    {
      "nct_id": "NCT03591874",
      "title": "Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease",
      "start_date": "2018-12-23",
      "completion_date": "2020-04-30",
      "enrollment": 0,
      "sponsor": "Ocugen"
    },
    {
      "nct_id": "NCT06574997",
      "title": "Expanded Access Program for RP in Adults",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "Retinitis Pigmentosa",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Ocugen"
    },
    {
      "nct_id": "NCT06388200",
      "title": "A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Retinitis Pigmentosa",
      "start_date": "2024-06-18",
      "completion_date": "2026-12-31",
      "enrollment": 0,
      "sponsor": "Ocugen"
    },
    {
      "nct_id": "NCT05203939",
      "title": "Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Retinitis Pigmentosa, Leber Congenital Amaurosis",
      "start_date": "2022-01-24",
      "completion_date": "2027-03",
      "enrollment": 0,
      "sponsor": "Ocugen"
    }
  ],
  "summary": {
    "total_trials": 12,
    "by_phase": {
      "PHASE2, PHASE3": 2,
      "": 2,
      "PHASE1, PHASE2": 3,
      "PHASE1": 1,
      "PHASE3": 3,
      "PHASE2": 1
    },
    "by_status": {
      "UNKNOWN": 1,
      "NO_LONGER_AVAILABLE": 1,
      "ACTIVE_NOT_RECRUITING": 2,
      "RECRUITING": 3,
      "COMPLETED": 2,
      "TERMINATED": 2,
      "AVAILABLE": 1
    },
    "active_trials": 5,
    "completed_trials": 2,
    "conditions": [
      "COVID-19",
      "Center Involved Diabetic Macular Edema, Diabetic Macular Edema",
      "Dry Eye",
      "Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction",
      "Geographic Atrophy",
      "Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease",
      "Retinitis Pigmentosa",
      "Retinitis Pigmentosa, Leber Congenital Amaurosis",
      "Stargardt Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:33.417560",
    "search_query": "Ocugen, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Ocugen,+Inc."
  }
}